Evidence map›Paper›PMID 39735596›Full record

ArticleFrontiers in oncology2024

Chronic myelogenous leukemia coexpressing V-e16a2, V-e13a2, e13a2, and e14a2

Yang Xu, Yuying Fan, Sijin Liu, Jianmei Chang, Caifeng Guo, Lanhui Chen, Wenzheng Guo, Jinwen Dang, Hongwei Wang, Yanhong Tan

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yang XuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yuying FanInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Sijin LiuInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jianmei ChangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Caifeng GuoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Lanhui ChenInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Wenzheng GuoInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Jinwen DangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Hongwei WangInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Yanhong TanInstitute of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The coexistence of three or more transcripts in one patient with chronic myeloid leukemia (CML) is rarely reported. Thus, the disease progression and drug response are still unknown. This case report aimed to explore the drug response of CML with variant transcripts and to enrich the clinical treatment of rare types of CML. A 66-year-old Chinese female patient was diagnosed with chronic myeloid leukemia-chronic phase (CML-CP) expressing four

Indexed as

BCR::ABL1chronic myelogenous leukemiae16a2 transcriptstyrosine kinase inhibitorsvariant transcript

Identifiers

PMID39735596
PMCPMC11672779

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.